Jim Simons
RXRX icon

Jim Simons’s Recursion Pharmaceuticals RXRX Stock Holding History

Jim Simons’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,400,605
Closed -$7.37M – 3561
2026
Q1 		$7.37M Buy
+2,400,605
New +$9.28M 0.01% 1147
2023
Q3 		– Sell
-350,000
Closed -$2.62M – 4041
2023
Q2 		$2.62M Sell
350,000
-65,561
-16% -$459K ﹤0.01% 1829
2023
Q1 		$2.77M Buy
415,561
+221,661
+114% +$1.76M ﹤0.01% 1823
2022
Q4 		$1.5M Buy
193,900
+178,700
+1,176% +$1.75M ﹤0.01% 2266
2022
Q3 		$162K Sell
15,200
-246,400
-94% -$2.5M ﹤0.01% 3447
2022
Q2 		$2.13M Buy
261,600
+83,200
+47% +$557K ﹤0.01% 2140
2022
Q1 		$1.28M Buy
+178,400
New +$1.9M ﹤0.01% 2564

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jim Simons's RXRX Position: Q2 2026 in Review

Jim Simons sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 2,400,605 shares — an estimated $7.37M sold.

Jim Simons first reported a position in RXRX in Q1 2022 and held it in 7 quarters. The position peaked at $7.37M in Q1 2026. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Jim Simons reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jim Simons sold 2,400,605 Recursion Pharmaceuticals shares in Q2 2026, an estimated $7.37M.
  • Jim Simons first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 7 quarters.
  • Jim Simons's Recursion Pharmaceuticals position peaked at $7.37M in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.